Details of the Drug Combinations

General Information of This Drug (ID: DMS1GYT)

Drug Name
Mirabegron   DMS1GYT
Synonyms Myrbetriq (TN)
Indication
Disease Entry ICD 11 Status REF
Overactive bladder GC50.0 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

11 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Mirabegron + Desipramine DC1FWT7 Desipramine Pharmacokinetics of Mirabegron [2]
Rifampicin + Mirabegron DC0VJUT Rifampicin Pharmacokinetics of YM178 [3]
Solifenacin + Mirabegron DC59FGX Solifenacin Overactive Bladder [4]
Tamsulosin + Mirabegron DCRN6VE Tamsulosin Cardiovascular [5]
Mirabegron + Acetaminophen DC5RAFG Acetaminophen Nephrolithiasis [6]
Mirabegron + Propiverine DCMBZ6N Propiverine Overactive Bladder (OAB) [7]
Mirabegron + Tolterodine DCYUXNZ Tolterodine Overactive Bladder (OAB) [7]
Solifenacin + Mirabegron DCXDZR6 Solifenacin Overactive Bladder (OAB) [7]
Tadalafil + Mirabegron DCPXLCS Tadalafil Pre-diabetes [8]
Tamsulosin + Mirabegron DCY82ZV Tamsulosin Nephrolithiasis [6]
Tamsulosin + Mirabegron DCWAMR7 Tamsulosin Overactive Bladder [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7445).
2 ClinicalTrials.gov (NCT01478568) To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken Together
3 ClinicalTrials.gov (NCT00776516) Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers
4 ClinicalTrials.gov (NCT01745094) A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
5 ClinicalTrials.gov (NCT01489696) A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin
6 ClinicalTrials.gov (NCT02095665) Ureteral Stent-related Pain and Mirabegron (SPAM) Trial
7 ClinicalTrials.gov (NCT02294396) Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
8 ClinicalTrials.gov (NCT05051436) The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
9 ClinicalTrials.gov (NCT02656173) A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)